Study Comparing the MiStent SES Versus the XIENCE EES Stent
Launched by ECRI BV · Mar 5, 2015
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- All comers" patients:
- • Male or female patients 18 years or older;
- • Presence of one or more coronary artery stenoses of 50% or more in a native coronary artery or in a saphenous venous or arterial bypass conduit suitable for coronary stent implantation.
- • The vessel should have a reference vessel diameter ranging from 2.5 mm to 3.75 mm (no limitation on the number of treated lesions, vessels, or lesion length); All lesions of the patient must comply with the angiographic inclusion criteria.
- • The patient is judged to be capable of providing voluntary informed consent and has been fully informed of the nature of the study, is willing to comply with all study requirements and will provide written informed consent as approved by the Ethics Committee of the respective clinical site.
- Exclusion Criteria:
- • Known pregnancy or breastfeeding at time of randomization;
- • Known contraindication or hypersensitivity to sirolimus, everolimus, cobalt-chromium, or to medications such as aspirin, heparin, bivalirudin, and all of the following four medications: clopidogrel bisulfate, ticlopidine, prasugrel, ticagrelor;
- • Concurrent medical condition with a life expectancy of less than 12 months.
- • The patient is unwilling/ not able to return for outpatient clinic at 1 month and 12 months follow-up.
- • Currently participating in another trial and not yet at its primary endpoint.
About Ecri Bv
ECRI BV is a leading clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a focus on improving patient outcomes, ECRI BV specializes in conducting rigorous clinical trials across various therapeutic areas, ensuring adherence to the highest standards of scientific integrity and regulatory compliance. The organization is committed to fostering collaboration with healthcare professionals, academic institutions, and industry partners to facilitate the translation of research findings into practical applications. ECRI BV's mission is to enhance the quality and accessibility of medical interventions, ultimately contributing to the improvement of global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Corbeil, , France
Nimes, , France
Poitiers, , France
Jena, , Germany
Leipzig, , Germany
Munster, , Germany
Ulm, , Germany
Wiesbaden, , Germany
Amersfoort, , Netherlands
Amsterdam, , Netherlands
Blaricum, , Netherlands
Emmen, , Netherlands
Leeuwarden, , Netherlands
Nijmegen, , Netherlands
Venlo, , Netherlands
Belchatow, , Poland
Bielsko Biala, , Poland
Chrzanow, , Poland
Tychy, , Poland
Zgierz, , Poland
Patients applied
Trial Officials
Ernest Spitzer, MD
Study Director
European Cardiovascular Research Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials